查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1853959

牛结核病诊断市场按检测类型、产品和最终用户划分 - 全球预测 2025-2032

Bovine Tuberculosis Diagnosis Market by Test Type, Product, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，牛结核病诊断市场将成长至 16.4816 亿美元，复合年增长率为 8.03%。

关键市场统计数据
基准年 2024 8.8785亿美元
预计年份：2025年 9.608亿美元
预测年份 2032 16.4816亿美元
复合年增长率 (%) 8.03%

本书对影响全球牛结核病诊断决策的科学、操作和政策因素进行了简明扼要而又权威的概述。

牛结核病仍然是动物健康领域的持续挑战，对畜牧业生产力、贸易诚信和公共卫生都造成了重大影响。牛病菌感染的诊断需要免疫学和分子生物学平台的精确性，实验室在实施筛检和确诊流程时必须权衡灵敏度、特异性和可操作性。诊断策略是监测计画、监管决策和市场准入通讯协定的基础，凸显了稳健且可互通的侦测框架的重要性。

近年来，技术成熟度和营运压力相互交织，重塑了相关人员评估诊断效能的方式。免疫测量、核酸扩增技术和实验室自动化的进步正在改变检测模式，而政策变化和供应链波动迫使实验室和采购团队重新评估供应商关係和紧急计画。因此，决策者需要平衡且基于证据的见解，以协调监管合规、畜群健康目标、成本效益高的实验室运作和诊断技术的推广应用。

本执行摘要总结了现代诊断技术的动态发展，探讨了监管和贸易环境的影响，并提供了基于细分市场的洞察，以指导采购、实验室部署和研究优先顺序的确定。它着重于可操作的分析，旨在支援在各种检测方式和终端用户环境中做出快速且合理的选择，并清晰地展现区域营运差异和策略供应商考量。

技术进步、综合监测框架和采购韧性如何从根本上重塑全球牛结核病诊断生态系统

技术创新、跨部门合作以及对综合监测的重新重视正在变革时期牛结核病的诊断格局。改进的免疫检测，包括更具选择性的抗原和多重检测平台，在不牺牲灵敏度的前提下提高了特异性，并减少了已接种疫苗和交叉反应人群中的假阳性结果。同时，核酸扩增方法变得更加便捷快速，使得确诊检测能够缩短週转时间，并提高了菌株层级流行病学的可追溯性。

在营运方面，实验室正在采用数位化工作流程和自动化技术来提高检测效率，同时保持品管。现场采样、实验室资讯管理系统和国家监测资料库之间的互联互通，提高了即时情境察觉，并有助于开展有针对性的干预措施。此外，「同一健康」理念正在加强兽医服务、公共卫生部门和环境机构之间的合作，鼓励跨部门资料共用和诊断标准的统一。

随着相关人员将韧性置于优先地位，市场动态也在改变。筹资策略日益强调供应商多元化、有效的第二供应商以及库存管理，以降低中断风险。不断变化的监管预期强化了这一转变，这些预期要求为新型检测方法提供更清晰的认证途径，并简化检验通讯协定以加快部署。总而言之，这些趋势正在加速诊断生态系统的现代化，并影响实验室、监管机构和产业合作伙伴的优先事项。

了解美国关税措施（截至 2025 年）对诊断试剂供应的多方面影响，包括供应链、采购和验证等方面。

2025年美国关税的累积影响为诊断供应链、采购计画和竞争定位带来了新的考量。关税主导的成本压力直接影响进口诊断设备和关键试剂，进而影响采购时机、库存策略以及国内生产和区域采购的相对吸引力。实验室和政府采购负责人在选择常规检测和确诊检测平台时，正在重新评估总到岸成本和物流前置作业时间。

除了对单价的影响外，关税还促使供应商和买家进行策略调整。先前将生产集中在单一地区的供应商正在加速近岸外包和多元化布局，以维持市场准入并保护其利润结构。这种转变影响了产品供应计划、售后服务支援模式和验证週期。因此，诊断公司在选择平台时，不仅要考虑价格波动，还要考虑服务的连续性和验证成本。

对于公共卫生和兽医部门而言，关税凸显了联合采购框架、集中采购和官民合作关係的重要性，这些机制能够利用规模效应来吸收贸易相关的成本衝击。同时，研发重点也在转变。为了在进口中断的情况下维持检测能力，对替代试剂、检测方法再製造以及现有平台互通性的投资正被优先考虑。这些动态的累积效应凸显了积极主动的供应链风险管理和协调一致的政策因应措施对于保障诊断准备工作的必要性。

基于全面细分的诊断洞察揭示了不同测试方式、产品系列和最终用户业务优先顺序之间的独特需求。

细緻的市场区隔视角有助于明确如何根据侦测类型、产品类型和终端使用者环境调整诊断策略。基于检测类型的市场分析区分了免疫学筛检（例如牛结核病检测、比较性单次皮内子宫颈检测）、血清学检测（例如酶联免疫吸附试验 (ELISA)）、细胞反应检测（例如γ干扰素检测）以及透过聚合酶炼式反应 (PCR) 进行的分子确认。皮内检测因其操作简便，仍然是现场筛检的首选；基于ELISA的检测可提供可扩展的血清学监测；γ干扰素检测能够实现早期检测，这可能透过细胞介导的免疫对抗措施实现；而PCR则可以进行病原体层面的确认和菌株鑑定。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 以 CRISPR-Cas12a横向流动化验对高密度牛中的牛结核病抗原进行超灵敏检测
  • 将智慧型手机红外线热成像技术与机器学习模型结合，用于酪农牛潜伏性结核病的早期筛检。
  • 开发用于按需同时检测牛结核病和其他呼吸道病原体的多路復用微流体实验室晶片平台
  • 引入携带式即时PCR诊断方法，用于在偏远牲畜交易站快速确诊牛结核病
  • 部署奈米抗体功能化的电化学生物感测器以提高牛结核病抗体监测计画的特异性和灵敏度
  • 新型γ干扰素释放试验的监管核准趋势及其对国家牛结核病根除策略的影响

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章牛结核病诊断市场（依检测类型划分）

  • 牛结核病检测
    • 比较性皮内子宫颈试验
    • 单次皮内子宫颈试验
  • ELISA
  • γ干扰素检测
  • PCR

第九章牛结核病诊断产品市场

  • 装置
    • ELISA 阅读器
    • PCR仪
  • 套件
    • 牛结核病检测套组
    • ELISA试剂套件
    • γ干扰素干扰素试剂套件
    • PCR试剂套件
  • 试剂
    • 抗原
    • 酵素
    • 引子和探针
      • 底漆
      • 探测

第十章牛结核病诊断市场（以最终用户划分）

  • 诊断实验室
  • 政府机构
  • 研究所
  • 兽医诊所

第十一章牛结核病诊断市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十二章牛结核病诊断市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十三章 各国牛结核病诊断市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十四章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Thermo Fisher Scientific Inc.
    • Zoetis Inc.
    • IDEXX Laboratories, Inc.
    • Bio-Rad Laboratories, Inc.
    • Merck & Co., Inc.
    • Neogen Corporation
    • HIPRA SA
    • Elanco Animal Health Incorporated
    • Biogal-Galed Laboratories Ltd.
    • VMRD, Inc.
Product Code: MRR-0D217D5AD942

The Bovine Tuberculosis Diagnosis Market is projected to grow by USD 1,648.16 million at a CAGR of 8.03% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 887.85 million
Estimated Year [2025] USD 960.80 million
Forecast Year [2032] USD 1,648.16 million
CAGR (%) 8.03%

A concise yet authoritative orientation to the evolving scientific, operational, and policy drivers shaping bovine tuberculosis diagnostic decision-making globally

Bovine tuberculosis remains a persistent animal health challenge with significant implications for livestock productivity, trade integrity, and public health interfaces. The diagnosis of Mycobacterium bovis infections demands precision across a range of immunological and molecular platforms, and laboratories must balance sensitivity, specificity, and operational feasibility when implementing screening and confirmatory workflows. Diagnostic strategies underpin surveillance programs, regulatory decisions, and market access protocols, which elevates the importance of robust, interoperable testing frameworks.

Recent years have seen a convergence of technological maturation and operational pressures that reshape how stakeholders evaluate diagnostic performance. Advances in immunoassays, nucleic acid amplification techniques, and laboratory automation have altered testing paradigms, while policy shifts and supply chain volatility force laboratories and procurement teams to reassess vendor relationships and contingency plans. As a result, decision-makers require balanced, evidence-based insights to align diagnostic adoption with regulatory compliance, herd health objectives, and cost-effective laboratory operations.

This executive summary synthesizes contemporary diagnostic dynamics, examines the regulatory and trade environment influences, and offers segmentation-based insights to inform procurement, laboratory deployment, and research prioritization. The emphasis is on actionable analysis that supports rapid, defensible choices across testing modalities and end-user settings, while maintaining a clear view of regional operational heterogeneity and strategic vendor considerations.

How technological advances, integrated surveillance frameworks, and procurement resilience are fundamentally reshaping bovine tuberculosis diagnostic ecosystems worldwide

Diagnostic landscapes for bovine tuberculosis are undergoing transformative shifts driven by technological innovation, cross-sector collaboration, and a renewed focus on integrated surveillance. Immunoassay refinements such as more selective antigens and multiplexed platforms are improving specificity without sacrificing sensitivity, thereby reducing false positives in vaccinated or cross-reactive populations. In parallel, nucleic acid amplification methods have become more accessible and faster, enabling confirmatory testing with reduced turnaround times and enhanced traceability of strain-level epidemiology.

Operationally, laboratories are embracing digital workflows and automation to scale throughput while preserving quality control. Connectivity between field sampling, laboratory information management systems, and national surveillance databases is improving real-time situational awareness and facilitating targeted interventions. Moreover, the One Health paradigm is strengthening collaborative ties between veterinary services, public health authorities, and environmental agencies, prompting cross-disciplinary data sharing and harmonized diagnostic standards.

Market dynamics are also shifting as stakeholders prioritize resilience. Procurement strategies increasingly emphasize supplier diversification, validated secondary sourcing, and inventory management to mitigate disruption risks. These shifts are reinforced by evolving regulatory expectations that require clearer evidentiary pathways for novel assays and streamlined validation protocols for emergency deployment. Taken together, these trends are accelerating the modernization of diagnostic ecosystems and shaping the priorities of laboratories, regulators, and industry partners.

Understanding the multifaceted supply chain, procurement, and validation consequences arising from United States tariff actions enacted during 2025 that affect diagnostic availability

The cumulative effects of United States tariff measures implemented in 2025 have introduced new considerations across diagnostic supply chains, procurement planning, and competitive positioning. Tariff-driven cost pressures have a direct impact on imported diagnostic instruments and critical reagents, which in turn influence procurement timing, inventory strategies, and the relative attractiveness of domestic manufacturing or regional sourcing. Laboratories and government purchasers are reassessing total landed costs and logistical lead times when selecting platforms for routine and confirmatory testing.

Beyond unit cost impacts, tariffs have catalyzed strategic shifts among suppliers and buyers. Vendors that previously concentrated manufacturing in single geographies are accelerating nearshoring and diversification initiatives to preserve market access and protect margin structures. This reorientation has implications for product availability timelines, after-sales support models, and validation cycles, since newly localized production lines often require regulatory re-submissions or additional quality audits. Consequently, diagnostic adopters must factor in not only price variance but also service continuity and validation overheads when selecting platforms.

For public health and veterinary authorities, tariffs have emphasized the importance of collaborative procurement frameworks, pooled purchasing, and public-private partnerships that can leverage scale to absorb trade-related cost shocks. At the same time, research and development priorities are adapting: investments in reagent substitutes, assay reformulation, and interoperability of legacy platforms are being prioritized to maintain testing capacity under disrupted import conditions. These cumulative dynamics underscore the need for proactive supply chain risk management and collaborative policy responses to safeguard diagnostic readiness.

Comprehensive segmentation-driven diagnostic insights that reveal distinct requirements across test modalities, product families, and diverse end-user operational priorities

A nuanced segmentation lens clarifies how diagnostic strategies must be tailored across test types, product categories, and end-user settings. Based on Test Type, market analysis differentiates between immunological screening such as Caudal Fold Test modalities with their Comparative Intradermal Cervical and Single Intradermal Cervical variants, serological assays like ELISA, cellular response measures exemplified by Gamma Interferon Assay, and molecular confirmation via PCR. Each test category offers a distinct mix of diagnostic attributes: the intradermal tests remain frontline for field screening with operational simplicity, ELISA-based tests provide scalable serological surveillance, Gamma Interferon assays deliver earlier detection in some cases through cell-mediated immunity measures, and PCR affords pathogen-level confirmation and strain characterization.

Based on Product, diagnostic ecosystems encompass Instruments, Kits, and Reagents that together form end-to-end testing workflows. Instruments range from ELISA readers to PCR machines, whose throughput, automation, and data integration capabilities influence laboratory efficiency and cost per test. Kits include tailored solutions for Caudal Fold Test Kits, ELISA Kits, Gamma Interferon Assay Kits, and PCR Kits, each requiring validation for specific host populations and use-cases. Reagents cover Antigens, Enzymes, and Primers and Probes, with primers and probes further disaggregated into primer and probe components critical for molecular specificity. Quality, cold-chain robustness, and batch-to-batch consistency of these inputs directly affect diagnostic reliability and regulatory acceptability.

Based on End User, diagnostic needs diverge across Diagnostic Laboratories, Government Agencies, Research Institutes, and Veterinary Hospitals. Diagnostic laboratories prioritize throughput, standardized quality control procedures, and regulatory compliance. Government agencies focus on surveillance integration, export-import implications, and outbreak response readiness. Research institutes emphasize assay development, validation, and epidemiological analytics, while veterinary hospitals require practical, rapid-result diagnostics that support clinical decision-making at the herd or individual animal level. Understanding these segment-specific priorities is essential to align product development, service models, and distribution strategies with real-world user constraints and expectations.

How distinct regional infrastructures, regulatory frameworks, and agricultural systems drive divergent diagnostic priorities and practical deployment strategies across global markets

Regional heterogeneity significantly shapes diagnostic adoption pathways, regulatory expectations, and supply chain architectures. In the Americas, well-established surveillance infrastructures and large commercial herds support routine deployment of both field screening tests and laboratory-based confirmatory assays. Laboratories in this region often prioritize high-throughput ELISA platforms and PCR confirmation for trace-back investigations, while also balancing the need for rapid point-of-care screening in remote production areas. Trade dynamics and cross-border disease management frameworks further incentivize harmonized diagnostic standards and collaborative surveillance initiatives.

Within Europe, Middle East & Africa, the diagnostic landscape is highly heterogeneous, encompassing regions with sophisticated laboratory networks alongside areas facing resource constraints. Regulatory harmonization efforts across parts of Europe provide a framework for standardized assay validation and mutual recognition, whereas in some Middle Eastern and African contexts, priorities include strengthening cold-chain logistics, local capacity building, and scalable, field-appropriate tests. Donor-supported programs and regional veterinary networks play a critical role in enabling access to diagnostics, while also creating opportunities for technology transfer and localized manufacturing to reduce dependency on long supply chains.

Asia-Pacific exhibits rapid modernization of diagnostic capabilities coupled with significant variation across national systems. Large-scale agricultural producers and research centers are investing in molecular confirmation and integrated data systems, yet smallholder-dominated regions emphasize low-cost, easy-to-use screening tests and decentralized sampling strategies. Cross-border trade, zoonotic risk awareness, and investments in laboratory accreditation are driving uptake of higher-sensitivity assays in some markets, while others adopt hybrid models that combine field screening with centralized confirmatory testing. Recognizing these regional contrasts is essential when designing distribution strategies, regulatory engagement plans, and capacity-building initiatives.

Commercial and technical strategies that define competitive advantage through assay quality, integrated support services, regulatory enablement, and resilient manufacturing footprints

Key company dynamics center on capabilities that span instrument innovation, kit formulation, reagent quality, and service delivery. Leading diagnostic firms and specialized manufacturers that invest in assay specificity, robust supply chains, and regulatory dossier development are better positioned to meet buyer expectations for validated, deployable solutions. Partnerships between instrument makers and reagent suppliers enhance compatibility and accelerate laboratory adoption through bundled offerings that simplify validation and reduce integration overhead.

Competitive differentiation increasingly relies on post-market support, training services, and digital enablement that streamline laboratory workflows. Companies offering laboratory information management integrations, remote calibration, and quality assurance programs add measurable value for large diagnostic networks and government programs. At the same time, upstream investments in assay research-particularly in antigen refinement and primer/probe design-are critical to maintaining clinical performance amid cross-reactivity challenges and evolving pathogen epidemiology.

Strategic moves such as regional manufacturing expansions, collaborations with academic groups for validation studies, and flexible commercial models that include reagent rental or reagent-as-a-service can materially influence market access. Firms that proactively address supply chain resilience, offer validated secondary sourcing, and provide clear regulatory support pathways for customers will be best placed to secure long-term institutional contracts and to support emergency response scenarios.

Practical and prioritized strategic interventions for diagnostic companies and institutional stakeholders to enhance validation, supply resilience, digital integration, and One Health collaboration

Industry leaders should prioritize a coordinated set of actions to strengthen diagnostic reliability, supply continuity, and market responsiveness. First, accelerating validation efforts across multiple matrices and host populations will reduce uncertainty when deploying assays in heterogeneous field conditions and facilitate regulatory acceptance. Investing in cross-laboratory proficiency testing and third-party validation studies builds confidence among procurement agencies and supports harmonized surveillance protocols.

Second, diversifying supply chains and expanding regional manufacturing or distribution hubs mitigates tariff and logistics risk while reducing lead times for critical instruments and reagents. Strategic partnerships with local manufacturers and contract development organizations can preserve product quality while improving responsiveness to sudden demand surges. Third, embedding digital connectivity into diagnostic workflows-through automated readers, cloud-based reporting, and interoperable LIMS-improves traceability, speed of reporting, and outbreak analytics, thereby delivering public health value beyond individual test results.

Fourth, companies should adopt flexible commercial models and invest in training programs for end users to enhance adoption and ensure correct test interpretation. Finally, alignment with One Health stakeholders through data-sharing initiatives and joint training fosters integrated responses to zoonotic risk and elevates the role of diagnostic evidence in policy-making and trade negotiations. Executing these recommendations will strengthen operational readiness and create competitive differentiation in a dynamic diagnostic environment.

A transparent and reproducible mixed-methods research approach that integrates technical literature, primary stakeholder interviews, and laboratory observations to validate diagnostic insights

The research underpinning this analysis combined structured reviews of peer-reviewed publications, regulatory guidance documents, and technical standards with primary qualitative interviews and facility-level observations. Secondary literature provided context on assay performance characteristics, regulatory pathways, and historical surveillance protocols, while an array of expert interviews with laboratory directors, veterinarians, and procurement specialists offered operational perspectives on adoption barriers and real-world workflows.

Primary data collection included semi-structured interviews to explore validation requirements, supply chain experiences, and post-market support expectations. Field observations in diagnostic laboratories and veterinary clinics informed assessments of throughput constraints, cold-chain practices, and staff training needs. Triangulation across these inputs ensured that conclusions reflect both technical performance metrics and practical operational realities. Quality control measures included independent review of technical summaries by subject-matter experts and cross-validation of key findings against public regulatory guidance and published assay evaluations.

The methodology emphasized transparency and reproducibility by documenting data sources, interview guides, and validation steps. Stakeholder engagement prioritized representativeness across laboratory types and geographical regions to capture heterogeneity in needs and capabilities. Where applicable, sensitivity checks and scenario analyses were used to test the robustness of recommendations under different operational and trade conditions.

A concise synthesis highlighting the imperative for interoperable, validated, and resilient diagnostic systems that support surveillance, trade, and public health objectives

Effective management of bovine tuberculosis diagnostics requires an integrated perspective that aligns technological capabilities with operational constraints and policy objectives. Diagnostic selection is not a purely technical choice; it intersects with regulatory frameworks, trade considerations, and the capacity of end users to implement and sustain testing workflows. The combined effect of evolving assay technologies, shifting procurement landscapes, and regional heterogeneity underscores the need for adaptive strategies that prioritize validation, resilience, and interoperability.

Decision-makers should focus on building modular diagnostic ecosystems where screening, confirmation, and data management components are interoperable and supported by clear validation evidence and supply chain contingencies. Cross-sector collaboration and investment in local capacity can reduce vulnerabilities and enable faster, evidence-based responses to outbreaks. Ultimately, strengthening diagnostic systems for bovine tuberculosis yields benefits that extend into public health, trade confidence, and animal productivity, making it a high-priority area for coordinated investment and policy attention.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of CRISPR-Cas12a lateral flow assays for ultrasensitive on-farm btb antigen detection in high-density cattle herds
  • 5.2. Integration of smartphone-enabled infrared thermographic imaging with machine learning models for early subclinical bovine tb screening in dairy operations
  • 5.3. Development of multiplexed microfluidic lab-on-a-chip platforms for simultaneous detection of bovine tuberculosis and other respiratory pathogens at point of need
  • 5.4. Implementation of portable real-time PCR diagnostics with lyophilized reagents for rapid confirmation of bovine tb in remote livestock trading hubs
  • 5.5. Deployment of nanobody-functionalized electrochemical biosensors to enhance specificity and sensitivity in bovine tb antibody surveillance programs
  • 5.6. Regulatory approval trends for novel interferon-gamma release assays and their impact on national bovine tuberculosis eradication strategies

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Bovine Tuberculosis Diagnosis Market, by Test Type

  • 8.1. Caudal Fold Test
    • 8.1.1. Comparative Intradermal Cervical Test
    • 8.1.2. Single Intradermal Cervical Test
  • 8.2. Elisa
  • 8.3. Gamma Interferon Assay
  • 8.4. PCR

9. Bovine Tuberculosis Diagnosis Market, by Product

  • 9.1. Instruments
    • 9.1.1. Elisa Readers
    • 9.1.2. Pcr Machines
  • 9.2. Kits
    • 9.2.1. Caudal Fold Test Kits
    • 9.2.2. Elisa Kits
    • 9.2.3. Gamma Interferon Assay Kits
    • 9.2.4. PCR Kits
  • 9.3. Reagents
    • 9.3.1. Antigens
    • 9.3.2. Enzymes
    • 9.3.3. Primers And Probes
      • 9.3.3.1. Primers
      • 9.3.3.2. Probes

10. Bovine Tuberculosis Diagnosis Market, by End User

  • 10.1. Diagnostic Laboratories
  • 10.2. Government Agencies
  • 10.3. Research Institutes
  • 10.4. Veterinary Hospitals

11. Bovine Tuberculosis Diagnosis Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Bovine Tuberculosis Diagnosis Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Bovine Tuberculosis Diagnosis Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Analysis
    • 14.3.1. Thermo Fisher Scientific Inc.
    • 14.3.2. Zoetis Inc.
    • 14.3.3. IDEXX Laboratories, Inc.
    • 14.3.4. Bio-Rad Laboratories, Inc.
    • 14.3.5. Merck & Co., Inc.
    • 14.3.6. Neogen Corporation
    • 14.3.7. HIPRA S.A.
    • 14.3.8. Elanco Animal Health Incorporated
    • 14.3.9. Biogal-Galed Laboratories Ltd.
    • 14.3.10. VMRD, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. AMERICAS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. NORTH AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. LATIN AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. EUROPE, MIDDLE EAST & AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. EUROPE BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. MIDDLE EAST BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASEAN BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GCC BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPEAN UNION BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. BRICS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. G7 BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. NATO BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BOVINE TUBERCULOSIS DIAGNOSIS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. BOVINE TUBERCULOSIS DIAGNOSIS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BOVINE TUBERCULOSIS DIAGNOSIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COMPARATIVE INTRADERMAL CERVICAL TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COMPARATIVE INTRADERMAL CERVICAL TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COMPARATIVE INTRADERMAL CERVICAL TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COMPARATIVE INTRADERMAL CERVICAL TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COMPARATIVE INTRADERMAL CERVICAL TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COMPARATIVE INTRADERMAL CERVICAL TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY SINGLE INTRADERMAL CERVICAL TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY SINGLE INTRADERMAL CERVICAL TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY SINGLE INTRADERMAL CERVICAL TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY SINGLE INTRADERMAL CERVICAL TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY SINGLE INTRADERMAL CERVICAL TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY SINGLE INTRADERMAL CERVICAL TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY GAMMA INTERFERON ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY GAMMA INTERFERON ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY GAMMA INTERFERON ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY GAMMA INTERFERON ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY GAMMA INTERFERON ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY GAMMA INTERFERON ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ELISA READERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ELISA READERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ELISA READERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ELISA READERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ELISA READERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ELISA READERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PCR MACHINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PCR MACHINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PCR MACHINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PCR MACHINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PCR MACHINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PCR MACHINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ELISA KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ELISA KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ELISA KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ELISA KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ELISA KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ELISA KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY GAMMA INTERFERON ASSAY KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY GAMMA INTERFERON ASSAY KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY GAMMA INTERFERON ASSAY KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY GAMMA INTERFERON ASSAY KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY GAMMA INTERFERON ASSAY KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY GAMMA INTERFERON ASSAY KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PCR KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PCR KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PCR KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PCR KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PCR KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PCR KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ANTIGENS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ANTIGENS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ANTIGENS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ANTIGENS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ANTIGENS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ANTIGENS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ENZYMES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ENZYMES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ENZYMES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ENZYMES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ENZYMES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ENZYMES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRIMERS AND PROBES, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRIMERS AND PROBES, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRIMERS AND PROBES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRIMERS AND PROBES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRIMERS AND PROBES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRIMERS AND PROBES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRIMERS AND PROBES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRIMERS AND PROBES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRIMERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRIMERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRIMERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRIMERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRIMERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRIMERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PROBES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PROBES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PROBES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PROBES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PROBES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PROBES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY GOVERNMENT AGENCIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY GOVERNMENT AGENCIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY GOVERNMENT AGENCIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY GOVERNMENT AGENCIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY GOVERNMENT AGENCIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY GOVERNMENT AGENCIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY VETERINARY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY VETERINARY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY VETERINARY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY VETERINARY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. AMERICAS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 169. AMERICAS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRIMERS AND PROBES, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRIMERS AND PROBES, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. NORTH AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, 2025-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 192. NORTH AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRIMERS AND PROBES, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRIMERS AND PROBES, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. LATIN AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, 2018-2024 (USD MILLION)
  • TABLE 208. LATIN AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, 2025-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 210. LATIN AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 212. LATIN AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, 2018-2024 (USD MILLION)
  • TABLE 214. LATIN AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRIMERS AND PROBES, 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRIMERS AND PROBES, 2025-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. LATIN AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRIMERS AND PROBES, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRIMERS AND PROBES, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRIMERS AND PROBES, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRIMERS AND PROBES, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. MIDDLE EAST BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. MIDDLE EAST BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, 2018-2024 (USD MILLION)
  • TABLE 262. MIDDLE EAST BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, 2025-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 264. MIDDLE EAST BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 266. MIDDLE EAST BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, 2018-2024 (USD MILLION)
  • TABLE 268. MIDDLE EAST BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, 2025-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 270. MIDDLE EAST BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRIMERS AND PROBES, 2018-2024 (USD MILLION)
  • TABLE 272. MIDDLE EAST BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRIMERS AND PROBES, 2025-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. MIDDLE EAST BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, 2018-2024 (USD MILLION)
  • TABLE 280. AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, 2025-2032 (USD MILLION)
  • TABLE 281. AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 282. AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 283. AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 284. AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 285. AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, 2018-2024 (USD MILLION)
  • TABLE 286. AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, 2025-2032 (USD MILLION)
  • TABLE 287. AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 288. AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 289. AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRIMERS AND PROBES, 2018-2024 (USD MILLION)
  • TABLE 290. AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRIMERS AND PROBES, 2025-2032 (USD MILLION)
  • TABLE 291. AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 292. AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 293. ASIA-PACIFIC BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. ASIA-PACIFIC BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. ASIA-PACIFIC BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. ASIA-PACIFIC BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 297. ASIA-PACIFIC BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, 2018-2024 (USD MILLION)
  • TABLE 298. ASIA-PACIFIC BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, 2025-2032 (USD MILLION)
  • TABLE 299. ASIA-PACIFIC BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)

TAB